宿主IL28B基因型联合病毒基因型对慢性丙型肝炎抗病毒疗效的预测
原帖由bjlichuan发表于 2011-3-30 16:27;摘要：目的 综合分析宿主IL28B基因型和丙型肝炎病毒（HCV）基因型对慢性丙型肝炎患者聚乙二醇干扰素联合利巴韦林抗病毒治疗疗效的影响。 方法 对120例慢性丙型肝炎患者进行全程联合治疗，其中92例患者完成了治疗后24周随访，同时分析HCV基因型及宿主IL28B基因型对治疗结束时应答（ETR）及持续病毒学应答（SVR）的影响。 结果 IL28B基因CC型在这组慢性丙型肝炎患者中占89%。在HCV基因1b型患者中，IL28B基因CC 型患者可以获得比非CC（N-CC）型更高ETR率（P＝0.0014）和SVR率（P＝0.0007），但在HCV基因非1b（N-1b）型患者中，CC型与N-CC型患者间的抗病毒疗效差异无统计学意义；在IL28B基因N-CC型患者中，HCV基因N-1b可以获得比1b型更高的ETR 率（P＝0.0350）和SVR率（P=0.0222），但在CC型患者中，HCV基因N-1b与1b型间的疗效差异无统计学意义。 结论 HCV基因型及宿主IL28B基因型对我国慢性丙型肝炎患者聚乙二醇干扰素联合利巴韦林抗病毒治疗疗效具有重要影响。联合检测宿主IL28B基因型和病毒基因型可以更加科学、准确地预测抗病毒疗效，为真正实现个体化治疗提供依据。 yaoming发表于 2011-3-30 21:35:
这是HCV研究的一个热点。只是可惜研究得不深入！
请看一下文章：
Results: 1 to 20 of 68
1.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group.
Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x.
PMID:21443535
Related citations
2.IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
Lange CM, Zeuzem S.
J Hepatol. 2011 Mar 24.
PMID:21440591
Related citations
3.High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial).Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM.
Gastroenterology. 2011 Mar 23.
PMID:21439960
Related citations
4.
Mallolas Masferrer J, Martínez-Rebollar M, Laguno Centeno M.
Gastroenterol Hepatol. 2011 Mar 22. Spanish.
PMID:21435743
Related citations
5.Treatment of acute HCV infection.
Grebely J, Matthews GV, Dore GJ.
Nat Rev Gastroenterol Hepatol. 2011 Mar 22.
PMID:21423258
Related citations
6.
Lens García S, Coto-Llerena M, Pérez Del Pulgar Gallart S, Forns Bernhardt X.
Gastroenterol Hepatol. 2011 Mar 18. Spanish.
PMID:21420759
Related citations
7.Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children.
Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J.
Hepatology. 2011 Mar 16. doi: 10.1002/hep.24298.
PMID:21413051
Related citations
8.Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.
Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R; Irish HCV Research Consortium, O'Farrelly C, Gardiner CM.
Proc Natl Acad Sci U S A. 2011 Mar 14.
PMID:21402922
Related citations
9.Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients with HCV infection.
Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M, Peck-Radosavljevic M.
Clin Gastroenterol Hepatol. 2011 Mar 10.
PMID:21397726
Related citations
10.Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms.
Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; for the DITTO-HCV Study Group.
PLoS One. 2011 Feb 24;6(2):e17232.
PMID:21390311 Free PMC Article
Free full text Related citations
11.Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.
Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS.
AIDS. 2011 Mar 27;25(6):761-766.
PMID:21378537
Related citations
12.Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C.
Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group.
Gastroenterology. 2011 Mar 1.
PMID:21376050
Related citations
13.IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.
Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.
PMID:21374656
Related citations
14.Estimating the net contribution of IL28B variation to spontaneous hepatitis C virus clearance.
di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; the Swiss HIV Cohort Study.
Hepatology. 2011 Feb 28. doi: 10.1002/hep.24263.
PMID:21360716
Related citations
15.Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group.
J Med Virol. 2011 May;83(5):871-878. doi: 10.1002/jmv.22038. Epub 2011 Feb 25.
PMID:21360545
Related citations
16.HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz'ko V, Dubins'ka G, Poveda JD, Poynard T.
Clin Res Hepatol Gastroenterol. 2011 Feb 25.
PMID:21354889
Related citations
17.IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group.
J Hepatol. 2011 Feb 24.
PMID:21354446
Related citations
18.IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS.
Genes Immun. 2011 Feb 24.
PMID:21346780
Related citations
19.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM.
Genome Med. 2011 Feb 8;3(2):8.
PMID:21345258
Related citations
20.Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.
Intervirology. 2011 Feb 16.
PMID:21325786
Related citations
页:
[1]